Recent Finacing
Recent Raise
Braveheart Bio is a San Francisco–based clinical-stage biotechnology company developing a selective cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM).
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Braveheart Bio.
